AMPH
Amphastar Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$26.93
+2.28%Oct 29, 2026, 10:00 UTC
Amphastar Pharmaceuticals announced that it will release its third-quarter 2026 results after the market closes on November 5, 2026.
Source:Aug 6, 2026, 23:04 UTC
Amphastar Pharmaceuticals is addressing an FDA warning letter at its IMS subsidiary.
Source:Aug 6, 2026, 20:05 UTC
Amphastar Pharmaceuticals reported financial results for the three months ended June 30, 2026, with net revenues of $183.9 million, GAAP net income of $30.3 million, and adjusted non-GAAP net income of $40.8 million.
Source:Jul 13, 2026, 00:00 UTC
Amphastar Pharmaceuticals appointed Anthony Pierce as a Class III director, effective July 9, 2026.